# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

> **NCT02183415** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 77 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 1356 BS, low dose
- **DRUG:** BI 1356 BS, medium dose
- **DRUG:** BI 1356 BS, high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183415
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183415, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*